Merck scores 1st U.S.-approved Ebola vaccine

The FDA Dec. 19 approved a vaccination for Ebola developed by Merck, the first vaccine for the disease to be approved in the U.S.

The vaccine, called Ervebo, protects against Zaire ebolavirus, the species of viruses that most commonly causes Ebola outbreaks, according to STAT. It is the virus responsible for the current long-running outbreak in the Democratic Republic of the Congo. 

Ervebo will likely be stockpiled by countries, including the U.S., as a guard against a possible bioterrorism attack, according to STAT

It is a single-dose vaccine that generates a quick immune response, with protection against the virus occurring within about 10 days and is approved for people 18 years or older. 

The FDA approval follows the European Commission licensing the vaccine on Nov. 11, according to STAT

Read the full article here

More articles on pharmacy:
Novartis plans giveaway of world's most expensive drug
Albertsons launches 1- to 2-hour prescription deliveries
Smart Pharmacy lays off most of workforce

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars